CONMED (NYSE:CNMD) Price Target Raised to $49.00

CONMED (NYSE:CNMD) had its price objective increased by Wells Fargo & Company from $46.00 to $49.00 in a research note published on Thursday morning,Benzinga reports. Wells Fargo & Company currently has an equal weight rating on the stock.

A number of other equities research analysts have also weighed in on CNMD. Zacks Research upgraded shares of CONMED from a “strong sell” rating to a “hold” rating in a report on Tuesday, August 11th. BMO Capital Markets started coverage on shares of CONMED in a research note on Wednesday, July 8th. They set a “market perform” rating and a $36.00 target price for the company. Piper Sandler reissued a “neutral” rating and issued a $45.00 target price (up from $39.00) on shares of CONMED in a report on Thursday, July 30th. Needham & Company LLC restated a “hold” rating on shares of CONMED in a research note on Monday, July 13th. Finally, Wall Street Zen raised CONMED from a “hold” rating to a “buy” rating in a report on Monday, July 20th. Seven investment analysts have rated the stock with a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Reduce” and a consensus target price of $44.00.

CONMED Stock Performance

Shares of CONMED stock opened at $44.21 on Thursday. The business has a 50-day simple moving average of $47.06 and a 200-day simple moving average of $41.45. The company has a debt-to-equity ratio of 0.60, a quick ratio of 0.69 and a current ratio of 1.49. CONMED has a one year low of $31.44 and a one year high of $53.66. The company has a market cap of $1.32 billion, a PE ratio of 18.27, a P/E/G ratio of 2.00 and a beta of 0.94.

CONMED (NYSE:CNMD) last issued its earnings results on Wednesday, October 28th. The company reported $1.04 earnings per share for the quarter, beating the consensus estimate of $1.00 by $0.04. CONMED had a net margin of 5.36% and a return on equity of 13.93%. The firm had revenue of $335.56 million for the quarter, compared to analysts’ expectations of $336.28 million. During the same quarter last year, the company earned $1.08 earnings per share. The firm’s revenue was down .7% compared to the same quarter last year. On average, equities research analysts forecast that CONMED will post 4.58 EPS for the current fiscal year.

Hedge Funds Weigh In On CONMED

Several large investors have recently bought and sold shares of CNMD. Bessemer Group Inc. grew its position in shares of CONMED by 46.5% during the first quarter. Bessemer Group Inc. now owns 116,429 shares of the company’s stock worth $4,117,000 after acquiring an additional 36,940 shares during the last quarter. Bank of America Corp DE acquired a new position in shares of CONMED in the 2nd quarter valued at $43,904,000. Fifth Third Bancorp raised its position in CONMED by 497.4% in the 1st quarter. Fifth Third Bancorp now owns 70,623 shares of the company’s stock valued at $2,497,000 after purchasing an additional 58,801 shares during the last quarter. Bank of New York Mellon Corp purchased a new stake in CONMED in the 2nd quarter valued at $9,531,000. Finally, BlackRock Inc. purchased a new stake in CONMED in the 2nd quarter valued at $157,783,000.

More CONMED News

Here are the key news stories impacting CONMED this week:

• Positive Sentiment: CONMED raised its fiscal 2026 EPS outlook to $4.54-$4.61, with the midpoint above the $4.54 analyst consensus. The company maintained revenue guidance of approximately $1.4 billion, in line with expectations. CONMED Reports Third Quarter 2026 Financial Results
• Positive Sentiment: Third-quarter adjusted earnings of $1.04 per share exceeded the $1.00 consensus estimate. JPMorgan raised its price target from $45 to $50, while Wells Fargo increased its target from $46 to $49, suggesting analysts see additional upside. CONMED Q3 Earnings Top Estimates
• Neutral Sentiment: Both JPMorgan and Wells Fargo retained neutral-style ratings—“neutral” and “equal weight”—despite their higher targets. This indicates improved valuation expectations but no strong bullish conviction.
• Negative Sentiment: Quarterly revenue of approximately $335.6 million was essentially in line with estimates but declined about 0.7% year over year. EPS also fell from $1.08 in the prior-year quarter, signaling limited near-term operating momentum. CONMED Q3 Profit Rises and Updates 2026 Guidance

CONMED Company Profile

CONMED Corporation is a medical technology company that develops, manufactures, and sells surgical devices and related equipment. Its products are used by hospitals, ambulatory surgery centers, and other healthcare providers in orthopedic and general surgery procedures.

The company’s orthopedic portfolio includes arthroscopy systems, powered surgical instruments, sports medicine products, tissue ablation systems, implants, and related accessories. Its general surgery offerings include electrosurgical equipment, insufflation systems, smoke evacuation products, surgical visualization technologies, and devices used in minimally invasive procedures.

Founded in 1970, CONMED serves healthcare customers through direct sales and distribution channels in the United States and international markets.